CLOVIS ONCOLOGY, INC.
BOULDER, CO

, an oral, small molecule inhibitor of poly (ADP-ribose) polymerase (PARP) 1, 2 and 3. Rucaparib is in advanced clinical development for the treatment of ovarian cancer and we are initiating clinical development for the treatment of metastatic castration-resistant prostate cancer patients. We maintain global rights to rucaparib. For more program details, see key events timeline below. In addition, we have two other product candidates: rociletinib; an oral mutant-selective inhibitor of epidermal growth factor receptor (EGFR), for which we have terminated enrollment in all ongoing sponsored clinical studies, though we continue to provide drug to patients whose clinicians recommend continuing rociletinib therapy. We are continuing analyses of rociletinib data to determine whether certain populations of patients may represent an opportunity for a partner committed to investing in further clinical development. Lucitanib; an oral, potent inhibitor of the tyrosine kinase activity of vascular endothelial growth factor receptors 1 through 3 (VEGFR1-3), platelet-derived growth factor receptors alpha and beta (PDGFR α/β) and fibroblast growth factor receptors 1 through 3 (FGFR1-3). Lucitanib was previously evaluated in breast and lung cancers. Development in breast and lung indications has ceased and we continue to provide drug to patients whose clinicians recommend continuing lucitanib therapy. Along with our development partner, Les Laboratoires Servier (Servier), we are continuing to evaluate development options for lucitanib. Our product development programs generally target specific subsets of cancer, and we seek to simultaneously develop, with partners, companion diagnostics that direct our product candidates to the patients most likely to benefit from their use. We believe this approach to precision medicine—to deliver the right drug to the right patient at the right time—represents the future of cancer therapy. Our lead product candidate under active development is At Clovis Oncology, we seek to support patients and caregivers by providing clear, up-to-date, accessible information about our products in development. Accordingly, we provide information about ongoing clinical trials and links to other To participate in a Clovis Oncology Clinical Trial, contact the Clovis Oncology Clinical Trial Navigation Service at 1-855-262-3040 (USA) or +1-303-625-5160 (ex-USA) or In our pursuit to improve the lives of people living with cancer, Clovis Oncology is committed to realizing the promise of precision medicine for cancer. We seek to develop targeted therapies to better serve patients and ensure the right drug gets to the right patient. We strive to provide relevant, accurate and balanced medical information about Clovis Oncology’s products and pipeline to support health care professionals, patients and caregivers. In the U.S. for more information on Clovis Oncology’s products, please contact the Medical Information department at 1-415-409-7220 (US toll), 1-844-CLVS ONC (1-844-258-7662; US toll-free), by email at We strive to provide relevant, accurate and balanced medical information about Clovis Oncology’s products and pipeline to support health care professionals, patients and caregivers. In the U.S. for more information on Clovis Oncology’s products, please contact the Medical Information department at 1-415-409-7220 (US toll), 1-844-CLVS ONC (1-844-258-7662; US toll-free), by email at